ProMIS Neurosciences Inc. (PMN)

Over the past six months, ProMIS Neurosciences' stock price has significantly declined. Key events impacting the stock include the FDA granting Fast Track designation to PMN310 for Alzheimer's treatment, progress in the PRECISE-AD Phase 1b clinical trial for PMN310, new peer-reviewed publications highlighting the selective targeting of toxic oligomers, and the company raising $21.6 million in gross proceeds.

There is no indication of typical demand seasonality for ProMIS Neurosciences, Inc.'s products and services. The demand for such medical treatments is generally driven by disease prevalence and clinical need rather than seasonal factors.

ProMIS Neurosciences, Inc. (PMN) is a clinical-stage biotechnology company focused on discovering and developing precision antibody therapeutics for neurodegenerative diseases. The company uses its EpiSelect™ platform to target Disease Specific Epitopes (DSEs) on misfolded proteins linked to neurological conditions. Its major product candidates include PMN310, a monoclonal antibody for Alzheimer's disease in Phase 1b clinical trial; PMN267, targeting ALS, Parkinson's disease, and Lewy body dementia; and PMN442, for Multiple System Atrophy (MSA). The company is also developing vaccines targeting amyloid-beta for AD prevention and alpha-synuclein for multiple synucleinopathies.

ProMIS Neurosciences, Inc. is headquartered in Toronto, Ontario, Canada, and has additional operations in Cambridge, Massachusetts, United States. The company's primary focus and operations are based out of these locations.

ProMIS Neurosciences has maintained a generally positive news sentiment over the past year, with a news sentiment score of 1.45. Key events positively affecting the company's reputation include the FDA Fast Track Designation for PMN310, successful clinical trial progress, and peer-reviewed publications.

ProMIS Neurosciences, Inc. has a diverse ownership structure, with institutional shareholders holding 464.30% of the stock, insiders holding 1,481.21%, and retail investors holding 0.00%. Major institutional owners include Ally Bridge Group (NY) LLC, Armistice Capital, LLC, Sphera Funds Management Ltd., Citadel Advisors LLC, and Great Point Partners LLC. The largest individual shareholder is Jeremy M. Sclar, who owns 7.25 million shares, representing 336.65% of the company.